Corporate News tagged:
Stem Cells (2)
Aug 18, 2021
REPROCELL signs MSA with TEXCELL for Master Cell Bank Manufacturing
Read about REPROCELL's Master Service Agreement with TEXCELL JAPAN a TEXCELL Group Company for GMP iPSC - Master Cell Banks (MCB) Manufacturing.
Mar 01, 2021
New publication on RNA reprogramming of endothelial progenitor cells to make clinically -relevant iPSCs
Read about REPROCELL's contribution to a novel publication detailing advancements in iPSC reprogramming. The paper describes techniques for reprogramming EPCs
Feb 16, 2021
Axion BioSystems makes REPROCELL a distributor of its Maestro systems and consumables
Read Axion BioSystems announcement of Bioserve Biotechnologies Pvt Ltd (REPROCELL) as the new distributor of its Maestro systems and consumables in India.
Jul 15, 2020
REPROCELL announce the launch of StemRNA™ Entero human iPSC-derived intestinal epithelial cells
Find out more about REPROCELL's launch of StemRNA Entero human iPSC-derived intestinal epithelial cells. a more clinically relevant alternative to Caco2 cells.
Oct 25, 2019
REPROCELL Receives MSCRF Grant to Accelerate Stem Cell Drug Discovery Capability for Enabling Neuronal Disease Research and Drug Development
REPROCELL will apply the funding towards the development of stem cell banking for iPSCs and NSCs derived from various neurodegenerative disease patients.
Sep 25, 2019
PRESS RELEASE: REPROCELL and NeuCyte enter distribution agreement in North America and Europe
This new distributorship will grant REPROCELL customers access to NeuCyte's pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons.
Aug 22, 2019
PRESS RELEASE: ABLE Biott Bioreactors now available in Europe
REPROCELL announce the launch of ABLE Biott Bioreactors in Europe. The lab-scale system will allow researchers to culture stem cells in suspension.
May 13, 2019
REPROCELL Launches cGMP suite in Kawasaki to Accelerate Development of iPSC-derived Glial Progenitors for treatment of CNS disorders
REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in Kawasaki City for production of iPS Cell-derived Glial Progenitors (iGRP) for treatment of CNS disorders.
Nov 29, 2017
REPROCELL Announces Research Collaboration with Q Therapeutics and Dr Mahendra Rao
Learn more about REPROCELL's collaborative research agreement with Q therapeutics to develop new iPS Cell therapies for central nervous system diseases
Nov 22, 2016
Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products
REPROCELL announces an entrustment contract with Healios K.K. for sample testing support of human clinical trials conducted by Healios.
Nov 16, 2016
Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development
Today, REPROCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. for the development of a 3D model system derived from human iPS cells.
Nov 16, 2015
A Joint Development with the National Cancer Center Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality
“ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to go on sale in December this year.
Nov 04, 2015
Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells
REPROCELL like to inform you that a patent application concerning an amplification method of hematopoietic stem cells which we applied for jointly with Nissan Chemical Industries, Ltd., has passed screening in the United States.
Oct 14, 2015
The REPROCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal
Group affiliate Stemgent Inc. (US) is pleased to announce the publication of a paper on state-of-the-art iPS cell production technology, entitled “RNA Reprogramming,” that was written collaboratively with the Whitehead Institute (USA).
Sep 08, 2015
REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells
REPROCELL is pleased to announce that our company has entered into an exclusive licensing agreement with Keio University regarding myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells.
Aug 26, 2015
Announcement: New High Performance Cryopreservation Solution – ReproCryo DMSO Free
Read more about how REPROCELL's new high-performance cryopreservation solution ReproCryo (DMSO free) is advancing the field of regenerative medicine.
Aug 14, 2015
Announcement of Award for Prototype Development of Large-Scale Production on Human-iPSC derived Cardiomyocytes
REPROCELL would like to announce that on August 3rd, 2015, one of our projects, “Prototype Development of a Large- Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells” (hereafter, “the project”) was selected to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016).
Jul 29, 2015
Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient”
REPROCELL is pleased to announce that on August 10th our company began sales of “ReproNeuro AD-patient,” diseased neurons made from iPS cells derived from Alzheimer’s disease patients.
Jul 21, 2015
Announcement: sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells
This is a notice that we will on August 3rd 2015 commence sales of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells.
Jul 01, 2015
Announcement of Award for Prototype Development of a Liver Cell Kit
REPROCELL is pleased to announce that one of our projects, “Prototype Development of a Liver Cell Kit Derived From Functional Human Induced Pluripotent Stem (iPS) Cells for Applications in Drug Discovery” has been selected as a recipient of Grant for Manufacturing, Commerce, and Service Innovation additionally allocated for FY 2014-2015.